Physician profile
Alon Davis
NPI 1962499657
$6,429.34
in general payments reported to CMS, 2019-2025
53 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $643 · 2021: $1,168 · 2022: $1,598 · 2023: $789 · 2024: $575 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Debt Forgiveness: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.68 |
| Debt Forgiveness | $180.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $714.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $515.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $500.05 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $488.62 | 2021-2023 | Mavyret, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $462.90 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $311.95 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $279.08 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.89 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $209.93 | 2019-2023 | Spravato |
| Baxter Healthcare | $180.73 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $170.10 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $167.03 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $163.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.10 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $151.39 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alon Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.